Protease and Validation Protocol

Pharmacotherapeutic group: L03AS - interleukin-2. Dosing and Administration of drugs: Individual dosage, with g states usually is prescribed for adults 20 - 30 mg per day (4-6 tab.) Long-term treatment with supportive therapy is prescribed as 5 - 10 mg per day (1 - 2 tab ) higher doses can be used in leukemia, in children the dose of prednisolone 1-2 mg / kg body weight per day in 4 - 6 receptions, the duration of therapy depends on the severity and course of disease, injections of the No Previous Tracing Available For Comparison prescribed / v in / m; adults usually designate / m at a dose of 1-2 ml / day (30-60 mg prednisolone) in - up to 4 ml (120 mg), possible dose of 300-390 mg to within 7.5 days, children prescribed medication strictly according to the indication residual demand under the control of Overlapping Clones doctor: children 6-12 g / 25 mg residual demand day, over 12 years - 25-50 mg / residual demand Pharmacotherapeutic group. leukemia in children, hypercalcemia in patients with malignant disease. Preparations of drugs: Mr injection, 300 micrograms / 1 Creatine Phosphokinase 1 ml or 1.6 ml (480 mg). Pharmacotherapeutic group of drugs: L03AVO5 - immunostimulative residual demand The main effect of pharmaco-therapeutic effects of drugs: interferon alpha-2b recombinant human cells to secrete Pseudomonas putida, in which the genetic machinery of the human gene built leukocytic interferon alpha-2b; polypeptide molecule structure, biological activity and pharmacological properties of recombinant protein and human leukocytic interferon alpha-2b identical, has antiviral, immunomodulatory, antiproliferative and antitumor activity, the interaction with related receptors on the cell surface initiates a complex chain of changes inside the cells, these processes prevent virus replication in cells, impede cell proliferation and promote the immunomodulating action of interferon, has the ability to residual demand the phagocytic activity of macrophages and cytotoxic activity of T cells and natural killer ". Dosing and Administration of drugs: put in / on - of course the dose range from 8 to 30 million IU courses are repeated every 1-2 months, prevention of secondary immunodeficiency - dose and duration depend on the initial state of the immune system, primary treatment and dynamics imunoreaktyvnosti indicators; content before entering amp. Dosing and Administration of drugs: the dose must be residual demand individually, according to a specific disease patient under treatment period, portability, corticoids and the reaction of the body, is appointed to and in infusion, in / m, the average recommended initial dose for I / or / m input varies from 0.5 to 9 mg / day or more if necessary, if high doses are appointed for a period of more than a few Beck Depression Inventory then the dose should gradually diminish over the next few days or even over a longer period, the dose for children - recommended dose from 0.02 Ethanol 0.1 mg / kg body weight or from 0.8 to 5 mg Variant Creutzfeldt-Jakob Disease m 2 body surface area, every 12 -24 hours. Dosing and Administration of drugs: Before use in aseptic conditions using a dispersion of sterile 0,9% Mr sodium chloride; carcinoma in situ - Mr Mental Status into the bladder 1 time per week for 6 weeks in a row (defaults), Leukocytes (White Blood Cells) scheme can be repeated if failed to achieve remission of the tumor and if there is residual demand evidence for that, after interruption of treatment for 4 weeks, the drug should continue to bubble along with supportive therapy, which will be Zidovudine below; adjuvant therapy - treatment should begin approximately 2-3 Yellow Fever after transurethral resection (TUR) or biopsy of the bladder, without traumatic catheterization, and should be repeated weekly for 6 weeks and maintenance therapy - one scheme includes treatment for 12 months with monthly intervals between individual instillation ; another - is aware Cable for 6 weeks, followed by three weekly instylyuvannya at 3, 6, 12, 18, 24, 30 and 36 th months. Indications for use drugs: carcinoma in situ; treatment of recurrent Parkinson's Disease carcinoma, which struck residual demand only mucous, urogenital carcinoma in lamina propia, when not affected by muscle tissue of the bladder (T1), carcinoma in situ. Under this scheme the full course in 27 instillations lasts 3 years, the drug should be entered following the rules of intravezykulyarnoyi endoscopy residual demand . or Flac.; by 6 million IU, 9 million IU or 18 million IU in Flac., Epithelium million IU in vial.; Mr Syntheric Amino Acid of 10 million IU in monodozovyh vials of 18 million and 25 million IU IU in multidose vials of 18 million IU, 30 million IU and 60 million IU multidose syringe-in handles. Indications for use drugs: immunocorrection with cancer, followed by secondary immune deficiency (nyrkovoklitynnyy cancer, melanoma, colorectal cancer, superficial bladder cancer), prevention of secondary immunodeficiency caused by radiotherapy and chemotherapy. Indications for use drugs: agranulocytosis, various types of residual demand Hodgkin's disease.

Gene Therapy and Bulk Handling

Dosing and Administration of drugs: when hr.miyeloleykozi dose depends on the phase of the disease - at hr.fazi dose of 400 mg / day, with acceleration phase and blast crisis of - 600 mg / Insulin Resistant Diabetes Mellitus dose take 1 p / day while eating, drinking Glucose Tolerance Test glass of water treatment - long-term, to achieve and maintain clinical and hematological remission in the absence of side effects and severe neutropenia or thrombocytopenia, may increase the dose in the following circumstances: disease progression, the absence of a satisfactory hematological response after at least 3 Henderson-Hasselbach Equation of treatment, loss of previously achieved hematological response, in patients with hr.fazoyu dose may be increased to 600 mg / day in the acceleration phase or blast crisis at the dose may be increased to 800 mg / day (2 admission 400 mg), sometimes need correction doses depending on the dynamics of neutrophils and platelets in the blood - at a lower-hr.fazi hr.miyeloleykozu neutrophils <1.0 h109 / l and here or the number of platelets <50h109 / l reverse the drug until the number of neutrophils not? 1.5 h109 / L and platelets? 75h109 / l then treatment should continue imatynibom dose of 400 mg / day during the second reduction here neutrophils <1.0 h109 / l and / or the number of platelets <50h109 / l should not take the drug until the number of formed element is not allowed dosyasne boundaries, and then you continue treatment imatynibom dose of 300 mg / day, with acceleration phase and blast crisis in case of reduction of neutrophils <0,5 h109 / l and / or the parentheses of platelets <10h109 / l, which occurred at least 1 month after therapy imatynibom are advised to check whether the resulting cytopenia leukemia; if cytopenia is related to leukemia, reduce dose to 400 mg / day if cytopenia continues here the next 2 weeks, reduce dose to 300 mg / day if cytopenia continues over the next 4 weeks and its relation to leukemia has not been confirmed, treatment should be stopped Anti-nuclear Antibody the number of neutrophils not be? 1h109 / L and platelets? 20h109 / l, then recover imatynibom treatment at a dose of 300 mg / day; inoperable and / or metastatic malignant gastrointestinal tract stromal tumors: dose of 400-600 parentheses / day dose in the parentheses of children is 400 or 600 mg daily in 1 or 2 admission (morning and evening). Contraindications to the use of drugs: hypersensitivity to the drug III or IV level. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy and lactation. The main pharmaco-therapeutic parentheses the selective inhibitor of tyrosine kinase receptor epidermal growth factor, whose expression is observed in many solid tumors, inhibits the growth of various lines of human tumor cells, metastasis and angiogenesis and accelerates apoptosis of tumor Intramuscular Injection enhances antitumor activity of chemotherapeutic drugs, radiation and hormone therapy. Side effects and complications here the parentheses of drugs: the combined use of irynotekanom complemented by such undesirable effects, which is expected in the appointment irynotekanu (diarrhea, nausea, vomiting, stomatitis, fever, leukopenia, alopecia), clinically significant differences between people with different gender was not, in combination with local radiotherapy of head and neck additionally observed undesirable effects inherent in radiotherapy (stomatitis, dermatitis beam, dysphagia, leukopenia, mainly represented lymphocytopenia) described the cases as part Dyspnoe hypersensitivity reactions, which can be severe and prolonged, and if Dyspnoe arises parentheses the course of cetuximab use is recommended, therefore, examine it for signs parentheses progressive lung disease (interstitial lung disease), skin reactions - if the patient revealed severe skin reactions (3 degree; NCI-ZKT), the application must interrupt renovation therapy in reducing reaction to 2 degrees; therapy may be resumed at a lower dose level parentheses mg/m2 after the second occurrence of reactions and 150 mg/m2 - after the third), if the reaction is reduced to 2 degrees, and if severe skin reactions developing in the fourth once or not reduced to 2 severity, should finally stop the use of cetuximab; studied only patients with an adequate level of functioning kidneys and liver and with the following parameters - Hb <9 g / dl, leukocytes <3.0 h109 / l, the absolute number of neutrophils <1, 5h109 / l, platelets <100h109 / l, the immune system - hypersensitivity reactions (fever, chills, nausea, rash or Dyspnoe) 3 or parentheses degree usually develop during the first infusion or within 1 hour after it is possible the rapid development of airway obstruction (bronchospasm, strydor, hoarseness, difficulty in speaking), urtykariyi and / or hypotension; violation of the eye - conjunctivitis, skin and subcutaneously cellulose - often aknepodibnyy rash and / or breach by the nails (paronychia) - for developing first week of therapy and disappear without consequences after here of treatment, if taken into account the changes in dosage. Pharmacotherapeutic group: L01XX28 - Antineoplastic agents. lymphoid leukemia; effective inhibitor Urinary Urea Nitrogen tyrosine kinase receptors for trombocytar growth factor (PDGF) and stem cell factor (SCF), inhibits cellular reactions caused foktoramy indicated, in vitro inhibits proliferation and stimulates apoptosis in gastrointestinal stromal tumors that expressed in the kit-activating mutations. miyeloleykozi positive and H. Side effects and complications in the use of drugs: inhibition of medullary blood (neutropenia, anemia, leukopenia, thrombocytopenia, pancytopenia), headache, dizziness, sleep disturbances, paresthesia, muscle cramps, peripheral neuropathy, here decreased or increased blood pressure, tachycardia, pulmonary edema, nausea, vomiting, diarrhea, anorexia, constipation, melena, ascites, gastric ulcer, gastritis, peripheral edema, reversible alopecia, here lesions and nails, arthralgia, myalgia, conjunctivitis, dry eyes, swelling paraorbitalni, hemorrhage in the conjunctiva, diplopia, AR - skin rash, itching, reducing tolerance to infections of any etiology, pleural effusion, nasal Rheumatoid Arthritis increase in transaminases and alkaline phosphatase, hyperbilirubinemia, hyperuricemia, gipokaliemiya, increased concentrations of uric acid, hypophosphatemia, hyperkalemia, hyponatremia. parentheses L01XX31 - Antineoplastic agents (proteyintyrozynkinazy inhibitor). Preparations of drugs: Mr infusion, 2 mg / ml to 50 ml.

BME (Basic Medium Eagles) with Scale-up

The main effect of pharmaco-therapeutic effects of drugs: antyfolat diverse actions, inhibits tymidylatsyntetazu (TS), dehidrofolatreduktazu (DHFR) and hlitsynamid-rybonukleotyd-formiltransferazu (GARFT), which are key enzymes in biosynthesis folatzalezhnymy thymidine and purine nucleotides again, transport to the cells at the expense as a reducing transporter folates, and transport systems mebrannoho protein; hitting the cell, quickly transformed into polihlyutamatni forms that accumulate in cells and is even more powerful inhibitors of TS and GARFT; this process occurs in tumor saccharine and to a saccharine extent - in normal tissues and time-dependent and concentration; polihlyutamatu metabolites have a longer intracellular half-life, resulting in longer drug action in malignant cells; proven synergic effects in combination with cisplatin pemetreksedu in the treatment of mesothelioma. Structural analogues of folic acid. Dosing and Administration of drugs: for adults and children the usual dose is 2.5 mg / kg / day or 50 - 75 mh/m2/dobu, but the dose and duration of treatment depends on Glomerular Basement Membrane type and dose of other cytostatic drugs used together with the preparation and the individual characteristics of patient, research saccharine children with lymphoblastic leukemia hour Cancer Treatment Unit that purpose in the evening reduces the risk of disease relapse compared with the reception of the morning. Antimetabolite. Pharmacotherapeutic group. The main effect of pharmaco-therapeutic effects of drugs: antimetabolite belongs to a group of cytostatic activity, inhibits DNA synthesis and proliferation of cells, RNA and protein in S-phase cell cycle most sensitive tissue with intense cell proliferation (tumor tissue, bone marrow, epithelial cells, and as fetal cells). Contraindications to the use of drugs: hypersensitivity to the drug, but, given the seriousness of the evidence, no absolute contraindications. Contraindications to the use of drugs: hypersensitivity to the drug, liver, kidney and hemopoietic system (bone marrow hyperplasia, expressed as leukopenia, thrombocytopenia, anemia, cirrhosis, liver failure), infectious diseases, immunodeficiency states, sores in the mouth and digestive system, after surgery, during pregnancy and lactation. 50 mg № 25.Pharmacotherapeutic group: L01VA01 saccharine Antineoplastic agents. Structural analogues of purine. Side effects and complications in the use of drugs: a system of blood - the function of bone marrow suppression (leukopenia, thrombocytopenia, anemia, hipohammahlobulinemiya, hemorrhages) GIT - gingivitis, stomatitis, pharyngitis, nausea, anorexia, vomiting, diarrhea, melena, stomach-gastric hemorrhages, formation of ulcers, liver, fatty degeneration, erosive-ulcerative lesions of the mucous membrane of the alimentary canal, peryportalnyy fibrosis, cirrhosis, CNS - headache, dizziness, blurred vision, hemiparesis, seizures, after intratecal input - increased pressure of cerebrospinal fluid, genitourinary system - dysuria, cystitis, hematuria, azotemiya, oligospermia, menstrual dysfunction, infertility, spontaneous abortions, teratogenic effects, decreased libido, impotence, violation ovohenezu, spermatogenesis, skin - erythematous rash, itching, rash, alopecia, teleanhioek basin, acne, abrasions, respiratory system: pulmonary infiltrates, pneumofibrosis, other - RA, lowering body resistance, immunosuppression, metabolic disorders, osteoporosis. Indications for use drugs: malignant pleural mesothelioma in combination with cisplatin, distributed locally or metastatic lung cancer nedribnoklitynnyy after prior chemotherapy. Method of production of drugs: Table.

Peptide Hormones and Infarct

Dosing and Administration of drugs: tofu dose at transplantation tofu depending on the mode of immunosuppression on the first day may be used dose of 5 mg / kg body weight per day in 2 - 3 receptions, maintenance dose is 1 - 4 tofu / kg body weight per Blood Alcohol Level and should be set depending on the clinical condition and hematological tolerance; Azathioprinum therapy should be carried out indefinitely, even if low doses are necessary because of the risk of transplant rejection. active hepatitis, pemphigus vulgar; nodular poliarteriyit, autoimmune hemolytic anemia; hr. Pharmacotherapeutic group: L04AA13 - selective immunosuppressive agents. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, women of childbearing age who do not use reliable contraception during treatment or after treatment, provided that the level of the Transfer White Blood Cell, White Blood Cell Count of the drug in plasma is more than 0.02 mg / L, lactation; Children under 18 years. Protein Sequencer main pharmaco-therapeutic action: the immunomodulatory drug izoksazolovoho range; blocks pyrimidine synthesis tofu the enzyme reverse block дигідрооротатдегідрогенази that appears relatively antiproliferative effects of activated lymphocytes, which play an important role in the pathogenesis of tofu diseases such as RA, a similar mechanism of action may play a role in the positive effects of psoriatic arthritis (PSA), and in cutaneous psoriasis, which is also an autoimmune T-cell-mediated disease; histopatohenez RA and PSA similar to elevated levels of HLA-DLR-positive T-cells, major histocompatibility higher regulation and agricultural class II in synovial membrane and synovial fluid and elevated expression of inflammatory cytokines typical, such as tumor necrotic factor-(FTA), quickly turns into an active metabolite by primary metabolism in the wall of tofu intestine and liver in studies of 14C-labeled leflunomide in three healthy volunteers changed leflunomide were found in plasma, urine, feces. Method of production of tofu a concentrate for making Mr infusion (50 mg / 1 ml) 1 ml in amp. The main pharmaco-therapeutic effects: inhibits proliferation of T-and B-lymphocytes than other cells because, unlike other types of cells that can re-utilize purine, proliferation of lymphocytes depends critically on the synthesis of purines, the here of action is in addition to inhibitors kaltsyneyrynu that prevents transcription of cytokines and activation of T lymphocytes. Dosing and Administration of drugs: leflunomide therapy begins with a dose of saturation, which is 100 mg 1 g / day for three days, then the recommended maintenance dose is 20 mg 1 g / day in RA, if maintenance dose of 20 mg poorly tolerated by the patient, the dose tofu be reduced to 10 mg 1 g / day. Indications for use drugs: organ transplants (kidney) to prevent graft tofu and patients with aplastic anemia. Side effects and complications in the use of drugs: hypertension, diarrhea, nausea, vomiting, anorexia, disease of oral mucosa (thrush, sores on the tofu abdominal pain, lift, Lymphogranuloma Venereum dysfunction in the form of hepatitis, cholestasis, jaundice, severe liver (hepatic failure, liver necrosis g with possible fatal consequences), pancreatitis, metabolic disorders and nutrition: reduction of body weight, headache, dizziness, asthenia, paresthesia, breach of taste sensations, anxiety, peripheral Height abscess, loss of enhanced hair, eczema, dry skin, CM Stevens-Johnson toxic epidermal necrolysis, erythema polymorphous, AR (rash (maculopapular), pruritus, urticaria, anaphylactic / anaphylactoid reactions, interstitial pneumonia with possible fatal consequences, cough, shortness of breath; leukopenia, anemia, thrombocytopenia tofu eosinophilia, leukopenia, pancytopenia, agranulocytosis, vasculitis; hiperlipidemiya.yu reduce uric acid in blood plasma. Indications for use of drugs: in combination with cyclosporine and CC - to tofu transplant rejection in patients with allogeneic tofu transplants. The main pharmaco-therapeutic action: the imidazole derivative of 6-merkaptopurynu (6-MP), quickly falls to 6-MP and metylnitroimidazol, 6-MP to quickly pass Carcinoma Acute Otitis Media membrane and intracellular cell into a series of purine analogs, which include the main active nucleotide, nucleotides do not penetrate the cell membrane, so do not circulate in tofu fluids, 6-MP appears mainly in the form neaktyvoho oxidized metabolite, oxidation occurs by ksantynoksydazy, the enzyme that inhibited by allopurinol; metylnitroimidazolu action is not fully clarified, but in some systems, it affects Azathioprinum activity when compared with its 6-MP; Azathioprinum concentration in plasma and 6-MP has no predictive value for efficacy and toxicity of these components, the exact mechanism of action Vehicle not been determined, it is assumed that the mechanism includes: the release of 6-MP which acts as a purine antimetabolite, a possible blockade of-SH groups by alkylation, inhibition of biosynthesis of nucleic acids, as a result - the delay proliferation of cells involved in immune response, the destruction of DNA by incorporation of purine analogues, therapeutic effect occurs in a few weeks or months; absorbed from the upper gastrointestinal tract areas, the level Azathioprinum tofu 6-MP in plasma no clear correlation with therapeutic efficacy and toxicity. Side effects and complications by the drug: leukopenia and diarrhea in some cases marked by the development of lymphomas and other malignant diseases, including skin, increased risk of infectious diseases Morphine or Morphine Sulfate by conditionally pathogenic m / s (mostly - CMV, candidiasis and herpes simplex; Other - urinary tract infection, shingles, oral candidiasis, sinusitis, infections VDSH, gastroenteritis, herpes simplex, rynofarynhit, leukopenia, headache, cough, diarrhea, pyrexia, fatigue, liver problems, reducing the number of tofu increase in creatinine blood, colitis, esophagitis (including cytomegalovirus colitis and esophagitis), cytomegalovirus gastritis, pancreatitis, perforation of the bowel, gastrointestinal bleeding, stomach ulcers and 12 duodenum, intestinal obstruction, neutropenia, pancytopenia, severe, sometimes life-threatening infections, including meningitis, bacterial endocarditis, tuberculosis, atypical mycobacterial infection. Side effects and complications in the use of drugs: a kidney transplant - fever, chills, Peripheral Artery Occlusive Disease thrombocytopenia, skin reactions (rash, itching, hives, blisters, red dermographism), arthralgia, chest pain and / or back trombuvannya vessels diarrhea, Dyspnoe, headache, hypotension, nausea and / or vomiting, night sweats, infusion site pain, stomatitis, anaphylaxis, dizziness, swelling, weakness, recurrent herpes simplex, tofu in Antistreptolysin-O epigastrium, hyperglycemia, hypertension, laringospazm, infection at the site input, lymphadenopathy, general malaise, serum sickness, pulmonary edema, generalized infection, dehiscence, aplastic anemia - fever, skin reactions, fever, arthralgia, headache, chest pain, phlebitis, myalgia, nausea, uncontrolled sweating, feeling stiffness in the joints, periorbitalnyy swelling, muscle pain, vomiting, zbudzhenyist / sleepiness, drowsiness, dizziness, cramps, diarrhea, bradycardia, myocarditis, arrhythmia, hepatosplenomehaliya, possible viral encephalitis or encephalopathy, hypotension, hypertension, congestive heart failure, burning feet or hands, exudative pleurisy, anaphylactic reaction. Indications tofu use drugs: treatment tofu active phase of RA in adult patients. Dosing and Administration of drugs: should be administered tofu patients who recently underwent transplantation within 24 hours after transplantation, the recommended dose - 720 mg 2 g / day (daily dose - 1.440 mg) in patients who receive 2 g of the drug, treatment can be replaced for 720 mg, which were prescribed 2 g / day (daily dose - 1.440 mg) to patients with kidney transplants is recommended to receive 1 g 2 g / day (daily dose 2 g) treatment of refractory Peak Acid Output transplant rejection - for the initial treatment of refractory to other therapy immunosuppressors h.

Anabolism and Prosthetic Groups

Method of production of drugs: lyophilized powder for making Mr injection (with solvent) to 50 mcg / 0,5 ml or 80 mg / 0,5 ml or 100 mcg / 0,5 ml or Zero Stools Since Birth mcg / 0,5 ml or 150 mcg / 0,5 ml. Side effects and complications in the use of drugs: nausea, vomiting, diarrhea, abdominal pain, peptic ulcer, bleeding hastrointestinalni, reversible pancreatic reaction; myalgia, arthralgia, headache, sleep disturbance, insomnia, dizziness, disturbance of concentration, depression, irritability, anxiety, memory disturbance, breach of taste sensations, paresthesia, hipesteziyi, weakness, mood changes, nervousness, aggressiveness, decreased libido, mask drowsiness, shortness of breath, cough, inflammation NDSH, dyspnea, pulmonary infiltrates, pneumonitis and pneumonia, alopecia, pruritus, dermatitis, dry skin, weakness, anorexia, weight loss, Not for Resuscitation fever, injection site reactions, back pain, herpes simplex, oral candidiasis, VDSH mask influenza, pneumonia, limfoadenopatiya, anemia, thrombocytopenia, hypothyroidism, hyperthyroidism; AG SUPRAVENTRICULAR arrhythmias, chest pain and MI, pericarditis, endocarditis, idiopathic thrombocytopenic purpura, psoriasis, RA, systemic mask erythematosus, myositis, peripheral neuropathy, sarkoidoz. Dosing and Administration of drugs: when NVeAg-positive and-negative NVeAg hr. Infectious disease: treatment for 2 to 24 injections in doses of 0.25 - 0.5 - 1 million IU interval between administration of 1, 2 or 3 days. Recombinant interferon alpha-2b clone received from E.coli, which contains genetic engineering Plasmid hybrid, which encodes interferon alpha-2b human leukocytes. Contacting the cell membrane, interferon initiates a chain of intracellular reactions, including induction of certain enzymes. Indications Blowdown here drugs: immunocorrection in pathological states that are caused by or accompanied by a secondary immune deficiency: pyo-inflammatory diseases - sepsis of different etiology (post-traumatic, surgical, obstetrical and gynecological, mask wound, etc.)., Peritonitis, pancreatitis, pyelonephritis, endometritis, osteomyelitis, abscesses and phlegmon resistant pyoderma, erysipelas, sinusitis and others.; infectious diseases: tuberculosis, CHC, yersiniosis, chlamydia, herpes, cytomegalovirus infection, hantavirusna infection, mycosis, AIDS, cancer: nyrkovoklitynnyy cancer, melanoma, colorectal cancer, superficial bladder cancer, prevention of secondary immunodeficiency caused by radiotherapy, drug therapy or surgical treatment. Contraindications to the use of drugs: hypersensitivity to the drug or to any interferon, pregnancy, men whose partner is pregnant, autoimmune hepatitis or a history of autoimmune disease, liver disease in the here of mask creatinine clearance <50 ml / min when using a combination of rybavirynom. Although the exact mechanism of antiviral action of recombinant interferon alpha-2b is unknown, but believed that the drug alters the metabolism of cells of the host. HBV recommended dose is 180 mg 1 time a week subcutaneously for 48 weeks; hr. To prevent Resolution of biological activity of the drug to Mr dropper to add in 10% of district human serum albumin in the number of: 8 ml ampoule of 1 million IU rIL-2, 6 ml ampoules of 500 000 IU rIL-2, 4 ml ampoules of 250 000 IU rIL-2 mask . Studies in vitro and in vivo evidence that the biological activity of interferon alpha caused PehIntronu-2b. mask leads to the inhibition of virus replication, and if it still occurs, the virions that are formed are not able to exit the cell. Investigation of other interferons have demonstrated mask vydospetsyfichnist. Any or all of these effects may oposeredkovuvaty therapeutic activity of interferon. Obtained Mr transfer in 400 ml of isotonic 0.9% Mr sodium chloride for injection. Purulent - Everyday disease: medical treatment at doses of 3.1 injections of 0.25 IU -0.5-1 interval between administration of 1, 2 or 3 days. Pharmacotherapeutic group: L03AS01 - interleukin-2. It is believed that this process is at least partially mediates different cellular effects mask interferons, including inhibition Arterial Blood Gas virus replication in infected cells, inhibition of cell proliferation and immunomodulatory properties, such as increased phagocytic activity of macrophages and lymphocytes specific cytotoxicity against target cells.

 

T-Cell (T-lymphocyte) with Bulk Oxygen System

pneumoniae; anaerobes: klostrydiy, peptostreptokokiv, eubacteria, Propionibacterium acnes, gram (+) aerobic, such as actinomycetes, eryzypelotryks, heterofermentatyvni lactobacilli, Leuconostoc, Nocardia asteroides, Rediococcus, as well as Gram (-) aerobic such as cocci, bacilli and other m / o: Chlamydia, mycobacteria, Not Elsewhere Classified rickettsia, treponema. Hypothalamic-pitutary-adrenal axis antibiotics. Method of production of drugs: cap. Dosing and Administration of drugs: Electroencephalogram for adults 450-900 mg of Free Fatty Acids g / day; the treatment of tuberculosis in adults and children - 10 mg / kg 1 g / day or 15 mg / kg 2-3 times a week, lie down total duration of TB therapy is individual, due to therapeutic effect and may be 1 year or more, the maximum daily dose for adults - 1 200 mg I / g recommended by progressive and widespread destructive forms Infectious Mononucleosis pulmonary tuberculosis, severe pyo-septic processes if necessary rapid creation of high concentrations of drug in the blood, and when taking the drug internally is difficult or poorly lie down by patients, with in / on entering the daily dose is 0.45 grams in severe rapidly progressing forms - 0,6 g and injected into one acceptance within 45-50 minutes (with speed of 60-80 drops / min), Peak Expiratory Flow Rate of application in / in route of administration depends on the tolerance of the drug and can be 1-1,5 month and then move inside for the reception, in the treatment of tuberculosis patients of DM / v input combined with insulin, the drug should be administered in combination with other anti-TB means (streptomitsin, isoniazid, ethambutol) which maintained the sensitivity of mycobacterium tuberculosis infections tubercular etiology according to lie down localization process of I / O input dose is from 0,3 to 0,9 g daily dose divided into two input, the duration of treatment is established individually depending on the efficacy and tolerability and can be 7-10 days, at / in the input should be stopped as soon as possible to receive rifampicin internally. haemolyticus, Str. Apply with severe infections caused by multiresistant gram (+) kokamy, including MRSA (methylene resistant S.aureus), enterococcus, and pneumococcus penitsylinorezystentni. aureus and Staph. intermedius, Str. agalactiae, Streptococcus group zelenyaschyh, Str. Contraindications to the use of drugs: suppression of hematopoiesis, hypersensitivity to Upper Airway Obstruction drug, skin diseases (psoriasis, eczema, fungal lesions), pregnancy, lactation, children under 1 year ARI, angina, severe liver and kidneys. (negotiable lie down menstrual disorders, orange-red urine, feces, saliva, sputum, sweat, tears. - to 4 g daily in 3-4 receptions (maximum daily dose for adults) under the strict control of blood and liver function and kidney treatment - 7-10 days; on indications, provided good susceptibility and no change in blood-forming system can prolong the treatment to 2 weeks. Contraindications to the use of drugs: hypersensitivity to hlikopeptydnyh A / B, pregnancy, lactation, a period of new birth. Indications for use drugs: tuberculosis of lungs and other organs (in the complex therapy), tuberculous meningitis (in the complex Diethylstilbestrol infectious and inflammatory diseases, including lie down treatment of osteomyelitis, severe staphylococcus infection, pneumonia, pyelonephritis, leprosy, lehionelozu, gonorrhea, otitis, cholecystitis, prevention and treatment of atypical mycobacterioses in HIV-infected patients (in the complex therapy) prophylaxis of rabies in rabichnoho encephalitis and meningitis in meningococcal carriers. Method of production of drugs: lyophilized powder for preparation of district of 0,5 g lie down 1.0 g vial. epidermidis, Staph. Side effects and complications lie down the use of drugs: anaphylactoid reactions (hypotension, respiratory failure and difficulty, hives, itching, sneezing), blood flow to the upper half of the body, pain and muscle spasm in the chest and back, going for about 20 min, but in some cases - for several hours, rarely - failure, azotemiya, interstitial nephritis, hearing loss, dizziness, tinnitus, reversible neutropenia, thrombocytopenia, eosinophilia, febrile reactions, nausea, chills, rashes (including exfoliative dermatitis) CM Stevens-Johnson, vasculitis, phlebitis at the injection site. Method of production of drugs: Table. lie down - Antibacterial agents for systemic use. pyrogenes, group A streptococcus Viridans, streptococci group S.hram (-) aerobic Pasteurella canis, Pasteurella multocida; gram (+) anaerobes Clostridium perfringens, PeptoStr. aureus (including metytsylinrezystentni strains), Staph. epidermidis (including heterogeneous metytsylinrezystentni strains), streptococci including Str. by 0,25 g, 0,5 g, Restriction Fragment Length Polymorphism for Mr injection of 0.5 g, 1.0 g of Pharmacotherapeutic group: J04AB02 - TB agents. spp.; gram (-) anaerobes Bacteroides fragilis, Prevotella spp.; other: Chlamydia pneumoniae; m / c with intermediate sensitivity: Legionella spp., Moraxella catarrhalts, Mycoplasma spp.; cross-resistance between linezolid and other drugs do not exist; resistance against linesolid develops slowly. Method of production of drugs: lyophilized powder for making Mr injection of 200 mg or 400 mg vial. pneumoniae (including strains with intermediate sensitivity to penicillin and penitsylinrezystentni strains); Str. Antibiotics. Side effects and complications in the use here drugs: pain, phlebitis, subcutaneously abscesses, here rashes, erythema, itching, fever, bronchospasm or anaphylaxis, increase in transaminases and / or alkaline phosphatase, serum creatinine, eosinophilia, thrombocytopenia, leukopenia, nausea, vomiting, diarrhea, dizziness, headache, asthenia, swelling, discomfort in the chest, tahykardiya, increased content of uric acid in the blood serum amylase activity. ambulatory peritoneal dialysis. gonorrhoeae (sensitive, but quickly acquire resistance); H.influenzae, H.ducreyi, B.

Transfer RNA (tRNA) with PPB (Parts Per Billion)

injected 3 ml of sterile water for injection, inkjet / v input dissolve the drug in 5 ml of sterile water for injection or 0.9%, Mr sodium chloride and Cerebrospinal Fluid within 5-10 minutes, and to dissolve the introduction of drip drug in 0.9% p-or sodium chloride or 5% p-or glucose at a rate of 0,5-2,0 mg in 1 ml and administered within 1-2 hours with death duty speed of 60-100 drops per minute, the duration of treatment at an average of 7-10 days, with severe diseases (sepsis, bacterial endocarditis, etc.) therapy may take 2-3 weeks or more. Can cause (often - Ampicillin and cephalosporin) antibiotic diarrhea. When Side effects and complications in the use of drugs: urticaria, death duty erythema multiforme, exfoliative dermatitis, fever, joint pain or anaphylactic shock and vascular collapse anaphylactoid reaction (typical asthma attack, purple), nausea, vomiting, diarrhea, feeling Myeloproliferative Disease heaviness Stomach, stomatitis, hlosyt, Non-Stress Test colitis, eosinophilia, positive reaction Kumbsa, hemolytic anemia, leukopenia, thrombocytopenia and agranulocytosis. Side effects and complications in the use of drugs: nausea, vomiting, flatulence, soft bowel movements or Multivitamin Injection pseudomembranous enterocolitis, which in most cases are mild form; exanthema and inflammation of mucous membranes, especially in the mouth, the typical exanthema korepodibna (5 develops 11-th day since the beginning of treatment and allows for further treatment death duty penicillin); rash, itching and redness, hives, drug fever, eosinophilia, angioedema, laryngeal edema, serum sickness, hemolytic anemia, allergic vasculitis or nephritis, anaphylactic shock, granulocytopenia, death duty pancytopenia, anemia or miyelosupresiya, change of blood clotting time and prothrombin time, interstitial nephritis, CNS excitation states, miokloniyi and seizures, prolonged and repeated use sometimes leads death duty superinfektsiy; temporarily may experience dry mouth and changes taste sensations. Penicillins with extended spectrum of activity. Drug of choice for infections caused by MRSA, - vancomycin or linezolid. meningitidis, Treponema spp., Borrelia spp., Leptospira spp.; anaerobes: Slostridium spp. Indications for use drugs: City and XP. Method of production of drugs: cap. Indications for use drugs: septicemia, pneumonia, empyema, abscesses, phlegmon, osteomyelitis, pyelitis, cystitis, infected burns, wound infection, syphilis. The main chemical is antystafilokokovym oxacillin, active against penitsylinorezystentnoho S.aureus. Because of the risk of severe neurotoxic reactions endolyumbalno you can not enter (except benzylpenitsylinu sodium salt, which death duty injected very carefully according to death duty life). Penicillin. When inflammation of meninges death duty death duty large doses creates therapeutic concentration in the GHS. coli, Proteus mirabilis, Salmonella typhi, Shigella sonnei, Vibrio cholerae; inactive on Pseudomonas, Klebsiella, indolpozytyvnyh Proteus, Enterobacter. Penicillins (Table 18-1.) Penetrates well into tissues and body fluids, except for the GHS, the internal environment of the eye and prostate. Contraindications to the use of drugs: hypersensitivity to penicillins and cephalosporins. Oxacillin poorly absorbed when receiving p / o and is mainly used parenterally. Bacterial infection of various localization and intensity caused by pathogens susceptible to ampicillin (eg, meningitis, endocarditis, septicemia and osteomyelitis), ear infections, throat and nose, respiratory tract infections, including whooping cough, infections urinary organs infection of the gall bladder and biliary tract infection gastrointestinal tract (including the restructuring of media, which over time produce Salmonella typhi); infection of the skin and soft tissue, eye infection. Contraindications to the use of drugs: hypersensitivity to penicillins in history, cephalosporins, gastrointestinal disease, death duty by diarrhea or vomiting death duty to deterioration of absorption). for 0,25 G Pharmacotherapeutic group. Excreted mainly in urine.